Stefan Woxström, Senior Vice President Europe and Canada, AstraZeneca, talks about the need for future-proofing healthcare systems, incentivising innovation and reimbursement.

Finding a way to combat the negative effects of ageing could save healthcare systems millions. Learn whether ageing could be the next big pharma market to take the world by storm.

Robyn Widenmaier (GSK) and Tabetha Sundin (AstraZeneca) discuss whether bids to improve gender parity could be the ticket to change in women’s health.

A new generation of doctors is making their way into the workforce, but is the pharmaceutical industry ready to change its tactics to engage these younger HCPs?

The value of medical affairs is not up for debate, but are companies allocating enough time and resources to make it the strategic function it can be?

A deal ends months of wrangling between the UK government and the ABPI, but what will it mean for the industry and the UK’s bid to become a life sciences superpower?

With compliance and regulatory hoops to jump through, medical affairs teams can be reluctant to try new tactics. This roundtable uncovers their relationship with risk and asks what the future holds.

Peter Ahnesorg, Global Hematology Franchise Head, Roche, talks about his background in biochemistry, his hopes for the haematology space and his approach to leadership.